The Amphetamine-Enhanced Stroke Recovery (AESR) Trial: Primary Part 1 Results (S45.003)

CONCLUSIONS:The studied treatment regimen was safe. Primary results will be presented.Study Supported by:NIH-NS39934Disclosure: Dr. Goldstein has received personal compensation for activities with Pfizer Inc. Dr. Goldstein has received royalty payments from Up To Date, Henry Stewart Talks, and Quantia. Dr. Goldstein has received research support from AGA. Dr. Rabadi has nothing to disclose. Dr. Reding has received personal compensation for activities with Acorda Therapeutics as a consultant. Dr. Lennihan has nothing to disclose. Dr. Good has received personal compensation for activities with Allergan, Inc. Dr. Good has received personal compensation in an editorial capacity for Handbook of Clinical Neurology, Vol. 110, Neurological Rehabilitation. Dr. Dromerick received personal compensation from Merck & Co. Inc., and INC Research as a consultant. Dr. Pura has nothing to disclose. Dr. Samsa has received personal compensation for activities with Pfizer Inc., Johnson & Johnson, AstraZeneca, and Bayer Pharmaceuticals Inc.

Source: Neurology - April 9, 2014 Category: Neurology Authors: Goldstein, L., Rabadi, M., Reding, M., Lennihan, L., Good, D., Dromerick, A., Pura, J., Samsa, G. Tags: Cerebrovascular Disease and Interventional Neurology: Rehabilitation, Recovery, and Complications Source Type: research